Progressive Multifocal Leukoencephalopathy (PML) Lawsuit News and Information
Rituxan Lawsuit
Side effects of Ritxan may result in the development of a rare, but often-fatal brain infection known as progressive multifocal leukoencephalopathy (PML). At least 57 Rituxan PML brain infection cases have been reported, with a 90% fatality rate.
All Articles Tagged With: "Progressive Multifocal Leukoencephalopathy (PML)"
Tysabri Brain Infection Risk Increases with Number of Infusions: FDA
The FDA has issued another warning about the risk of brain infections from Tysabri, indicating that the more infusions a patient receives of the multiple sclerosis drug, the higher their risk of contracting progressive mutifocal luekoencephalopathy (PML), a rare and often fatal infection in the brain.
Additional PML Brain Infection Cases Linked to Tysabri and Rituxan
New cases of a rare brain infection, progressive multifocal leukoencephalopathy (PML), have been liked to the lymphoma and arthritis drug Rituxan and the multiple sclerosis (MS) drug Tysabri. The cases have regulators in the U.S. and Europe searching for ways to reduce the risks of patients developing the often fatal brain infection.
Tysabri Reactivates JC Virus Linked to Rare Brain Disease: Study
A new study indicates that side effects of Tysabri, a multiple sclerosis drug, reactivates and strengthens a virus that can cause a deadly brain infection, known as progressive multifocal leukoencephalopathy (PML). Tysabri was briefly removed from the market in 2005 after several patients died from the brain infection, and at least 13 Tysabri PML [...]
Kidney Transplant Drugs Receive New Warnings About Infection Side Effects
The FDA is requiring new warnings on several immunosuppressant drugs designed to prevent renal transplant patients from rejecting new kidneys. The new labeling will warn users of potential side effects that may increase the risk of infections due to a suppressed immune system.
PML Brain Infection from Tysabri Reported in 10th Patient
Biogen Idec Inc. is reporting that another brain infection from Tysabri has been discovered among users of their multiple sclerosis drug, which is at least the 10th case reported in the last three years.
Recall for Raptiva Finalized Due to Brain Infection Risk
The complete recall of the psoriasis drug Raptiva throughout the United States and participating countries of the European Union will be finalized this week, after sales were suspended earlier this year due to the risk of serious Raptiva side effects, including a fatal brain infection known as progressive multifocal leukoencephalopathy (PML).
Rituxan Fatal Infections Lead FDA to Review Risk of Side Effects
Following reports that link side effects of Rituxan to fatal brain infections, the FDA is reviewing whether users of the cancer-fighting drug should use the medication for shorter periods of time or take “drug holidays” to reduce the risk.
Rituxan PML Brain Infections Reported in 57 People
A new study indicates that at least 57 patients being treated with the lymphoma-fighting drug Rituxan have developed a rare brain infection, known as progressive multifocal leukoencephalitis (PML), and the cases have involved a 90% fatality rate.
Tysabri Brain Infection Reported in another Multiple-Sclerosis Patient
According to a report in the Wall Street Journal, another multiple sclerosis patient has developed a rare and often fatal brain infection, known as progressive multifocal leukoencephalopathy, or PML, as a possible side effect of Tysabri.
Contact a Lawyer
Submit information about your potential case to be reviewed by an attorney.
